MarginsXMarginsX
Home › Markets › Health Care › AGEN

Agenus Inc. (AGEN)

AGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.29
-6.54% on the day
Market cap
$284.6M
Micro cap
Revenue · 2025
$114.2M
+10.4% on 2024
Net income · 2025
-$3.1M
-2.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/0001193125-26-108632-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAGEN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2000
SEC CIK0001098972
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$114.2M
Net income-$3.1M
Operating income-$20.2M
Net margin-2.7%
Operating margin-17.7%
Revenue growth+10.4%
Cash$3.0M
Total assets$226.8M
P/E (computed)Net income was not positive
P/S (computed)2.5×

Warning signs

Cash runway
7.7 months
$66.9M cash at September 30, 2026
Share count, 1 year
+33.0%
2025-11-07 to 2026-11-03 · +137.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the filing date of this Quarterly Report on Form 10-Q."
10-Q 2026-11-05
Cash and burn$66.9M cash; operating cash flow -$26.0M a quarter.Report 2026-09-30
Shares outstanding45,246,510 (2026-11-03); 34,008,349 a year earlier; 381,495,471 three years earlier. 3y figure adjusted for splits (1-for-20 overall).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-20 on 2024-04-12Source 2024-04-12
Shelf and offerings, 12 months4 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$31.5M$2.7M-$20.1M$66.9M$35.1M$133.9M10-Q 2026-11-05
Q2 2026
2026-06-30
$34.5M-$567K-$31.2M$18.7M$30.1M$132.7M10-Q 2026-08-07
Q1 2026
2026-03-31
$33.7M$39.2M-$36.0M$35.0M$30.2M$123.9M10-Q 2026-05-11
Q4 2025
2025-12-31
$34.2M-$10.6M-$16.6M$3.0M$89.3M$114.2M10-K 2026-03-16
Q3 2025
2025-09-30
$30.2M$63.9M-$14.7M$3.5M$34.2M$106.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$25.7M-$30.0M-$20.2M$9.5M$33.9M$101.7M10-Q 2026-08-07
Q1 2025
2025-03-31
$24.1M-$26.4M-$25.6M$18.5M$33.6M$99.5M10-Q 2026-05-11
Q4 2024
2024-12-31
$26.8M-$46.8M-$28.7M$40.4M$33.2M$103.5M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-09-11
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-05-13

Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.9%
1 month-3.2%
3 months-3.9%
Year to date+114.3%
1 year+55.4%
From 52-week high-32.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
DTILPrecision BioSciences Inc.$7.28-3.77%$277.6M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier